SCHEMBL7538375

SCHEMBL7538375

COc1ccc(C)cc1S(=O)(=O)Nc1ccc(NS(=O)(=O)c2ccc3c(c2)oc(=O)n3C)cc1

nearest known ligand 0.74

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.70
HTT P42858 3/20 0.68
SMN1; SMN2 Q16637 1/20 0.68
ALDH1A1 P00352 2/20 0.64
TSHR P16473 1/20 0.64
PKM P14618 10/20 0.64
MEN1 O00255 4/20 0.64
KMT2A Q03164 4/20 0.64
GFER P55789 1/20 0.64
LMNA P02545 5/20 0.61
POLB P06746 1/20 0.60
TDP1 Q9NUW8 1/20 0.60
USP2 O75604 1/20 0.56
GLA P06280 1/20 0.56
MAPT P10636 1/20 0.56
RAB9A P51151 1/20 0.56
HPGD P15428 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7541039 0.81 PKM (0.75) TP53HTTSMN1; SMN2ALDH1A1TSHR
SCHEMBL7508002 0.81 PKM (0.56) TP53HTTSMN1; SMN2ALDH1A1TSHR
SCHEMBL7500569 0.80 KMT2A (0.59) TP53HTTSMN1; SMN2ALDH1A1TSHR
SCHEMBL7534161 0.79 HTT (0.76) TP53HTTSMN1; SMN2ALDH1A1TSHR
SCHEMBL7537999 0.78 PKM (1.00) TP53HTTSMN1; SMN2ALDH1A1TSHR
SCHEMBL7537372 0.78 MEN1 (1.00) TP53HTTSMN1; SMN2ALDH1A1TSHR
SCHEMBL7505784 0.78 PKM (1.00) TP53HTTSMN1; SMN2ALDH1A1TSHR
SCHEMBL7543496 0.77 PKM (1.00) TP53HTTSMN1; SMN2ALDH1A1PKM
SCHEMBL7543535 0.77 TP53 (0.59) TP53HTTSMN1; SMN2PKMLMNA
SCHEMBL7536317 0.76 TP53 (0.71) TP53HTTSMN1; SMN2ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170007608-A1 ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE AGIOS PHARMACEUTICALS INC (US) 2017-01-12 US disclosed
EP-2427441-B1 PKM2 ACTIVATORS FOR USE IN THE TREATMENT OF CANCER AGIOS PHARMACEUTICALS INC (US) 2016-12-14 EP disclosed
US-20140249150-A1 ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE AGIOS PHARMACEUTICALS, INC (US) 2014-09-04 US disclosed
US-8501953-B2 PKM2 modulators for use in the treatment of cancer AGIOS PHARMACEUTICALS, INC (US) 2013-08-06 US disclosed
WO-2013056153-A1 ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE KUNG CHARLES (US) 2013-04-18 WO disclosed
US-20120122849-A1 PKM2 MODULATORS FOR USE IN THE TREATMENT OF CANCER AGIOS PHARMACEUTICALS, INC. 2012-05-17 US disclosed
WO-2010129596-A1 PMK2 MODULATORS FOR USE IN THE TREATMENT OF CANCER AGIOS PHARMACEUTICALS, INC. (US) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122849-A1 PKM2 MODULATORS FOR USE IN THE TREATMENT OF CANCER PDK2, PDK1, PDK3 TP53 302/4885HTT 4166/4885SMN1; SMN2 4240/4885
US-20140249150-A1 ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE PDK1, PC, PDK2 TP53 722/4885HTT 2863/4885SMN1; SMN2 1229/4885
US-20170007608-A1 ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE PDK1, PC, PDK2 TP53 722/4885HTT 2863/4885SMN1; SMN2 1229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.